http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-20001734-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0264ab149dd139d522f7f14b1a3ea9e2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 1998-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e52fa114065f342ff60e970f382ddfbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7240188cdd84ac68f458668dde001f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8fd06a834cfdbd8afe443024cd70e8a |
| publicationDate | 2000-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-20001734-A3 |
| titleOfInvention | Pharmaceutical composition and its use |
| abstract | A pharmaceutical composition for the treatment of age-dementia of the Alzeimer type comprising as active ingredients compound (a) selected from 1- (2-naphth-2-ylethyl) -4- (3-trifluoromethylphenyl) 1,2,3,6-tetrahydropyridine and compound I where the substituents are as defined above, optionally from one of the pharmaceutically acceptable salts thereof, and the compound (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts. When compound (a) is other than 1- (2-naphth-2-ylethyl) -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine or a pharmaceutically acceptable salt thereof, compound (b) is an acetylcholinesterase inhibitor . |
| priorityDate | 1998-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 142.